Marijuana Dependence Clinical Trial
Official title:
Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics
This study aims to understand THC pharmacology and the safety of cannabis vaping, including the pharmacology and safety of co-administration of nicotine and THC. The study is designed as a within-subjects single-blinded crossover study. Fourteen smokers of tobacco cigarettes and cannabis will switch between three conditions, namely: (a) vaping cannabis leaf, (b) vaping tobacco containing nicotine and (c) vaping a combination of cannabis leaf and tobacco containing nicotine. All participants will vape each product with the PAX loose-leaf vaporizer. The study will be conducted during three outpatient visits separated by at least 48 hours. The order of treatment (cannabis leaf, tobacco with nicotine, cannabis leaf & tobacco with nicotine) will be counterbalanced between subjects. Subjects will be blinded to the content of the vaporizer on the study day but will be told during screening that they will vape cannabis alone, tobacco alone, and cannabis plus tobacco with nicotine.
Electronic cigarettes (e-cigarettes) have proliferated at a rapid rate since their introduction into the US market in 2007, and their use as a form of nicotine delivery far outpaced the science base. Although the design of these devices continues to evolve, we have previously described nicotine intake, systemic retention, pharmacokinetics, and vaping behavior associated with self-administration of e-cigarettes. We demonstrated that while the shape of the plasma nicotine concentration-time curve for e-cigarettes is similar to tobacco cigarettes, the maximum plasma nicotine concentration is, on average, lower for e-cigarettes. During ad libitum access, e-cigarettes were vaped intermittently in groups of 2-5 puffs or single puffs such that plasma nicotine levels rose gradually and peaked at the end of the 90-minute session. This differs from the rapid increase in plasma nicotine observed during controlled use of e-cigarettes or during tobacco cigarette smoking. Taken together, these results indicate that e-cigarettes have the potential to produce and sustain nicotine addiction but their use and abuse liability may differ from tobacco cigarettes. The study is designed as a within-subjects, single-blinded crossover study. Fourteen smokers of tobacco cigarettes and cannabis will switch between three conditions, namely: (a) vaping cannabis leaf, (b) vaping tobacco containing nicotine and (c) vaping a combination of cannabis leaf and tobacco containing nicotine. All participants will vape each product with the PAX loose-leaf vaporizer, which will be purchased by the study team. The cannabis leaf will be obtained through the National Institute on Drug Abuse Drug Supply Program. The tobacco-containing nicotine, used in conditions (b) and (c) will come from commercially available Marlboro brand cigarettes. The same amount of cannabis or tobacco will be used in all conditions. The study will be conducted during three outpatient visits separated by at least 48 hours. The order of treatment (cannabis leaf, tobacco with nicotine, cannabis leaf & tobacco with nicotine) will be counterbalanced between subjects. Subjects will be blinded to the content of the vaporizer on the study day but will be told during screening that they will vape cannabis alone, tobacco alone, and cannabis plus tobacco with nicotine. While scientists struggle to keep up with the latest electronic cigarette trends, the use of these devices for cannabis rather than nicotine is increasingly prevalent. Electronic cigarette use is not restricted to nicotine. Marijuana, the most widely used illicit drug has traditionally been combusted but the vaping of loose-leaf marijuana and THC oil has been increasing. the latest national data show that 7.6% of current marijuana users (past 30 days) and 9.9% of ever cannabis users (lifetime) administered THC through a vaporizer or electronic device (the study did not differentiate between vaporizers and electronic devices like e-cigarettes). The prevalence of vaped marijuana or THC is higher among younger adults. Prevalence of vaped marijuana/THC among 18-24 and 25-34 year-old ever marijuana users was 19.3% and 16.3%, respectively, compared to 8.8% for 35-49 year-olds and 5.7% for those 50 years and over. A recent study also showed high rates of cannabis vaping among high school students (18.0% among ever e-cigarette users). Smoking of a combination of tobacco and marijuana in cigarette form is also common, particularly in Europe. However, very little is known about the safety and pharmacokinetics of this co-administration making it a critical area of research. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00875836 -
Buspirone Treatment for Marijuana Dependence
|
Phase 4 | |
Completed |
NCT00893269 -
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
|
Phase 1 | |
Completed |
NCT00490269 -
Ph1 Marinol Interaction Study - Part 2 - 1
|
Phase 1 | |
Completed |
NCT02579421 -
Hormones and Reduction in Co-users of Marijuana and Nicotine
|
N/A | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT00373295 -
Effect of Baclofen on Marijuana Withdrawal and Relapse
|
Phase 2 | |
Active, not recruiting |
NCT01827332 -
Effect of Oxytocin on Craving and Therapy Response
|
N/A | |
Completed |
NCT01335789 -
Effect of Oxytocin on Stress in Marijuana Users
|
N/A | |
Terminated |
NCT00438139 -
Ph1 Marinol Interaction Study - Part 1 - 1
|
Phase 1 | |
Completed |
NCT02439814 -
Pregnenolone and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT01347762 -
Nabilone for Cannabis Dependence: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT01039415 -
Attempts to Stop/Reduce Marijuana Among Dependent Users
|
N/A | |
Completed |
NCT00270803 -
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
|
N/A | |
Completed |
NCT01020019 -
Combined Pharmacotherapy for Cannabis Dependency
|
Phase 2/Phase 3 | |
Completed |
NCT02030665 -
Marijuana Treatment Project 4
|
N/A | |
Completed |
NCT00107588 -
Marijuana Treatment Project - 3
|
N/A | |
Completed |
NCT02011516 -
Baclofen Effects on Marijuana Dependence
|
Phase 2 | |
Recruiting |
NCT00598052 -
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy
|
N/A | |
Completed |
NCT00374127 -
Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
|
Phase 2 | |
Completed |
NCT00350649 -
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
|
Phase 2 |